Fundamental considerations in the design of fluorine-18 labeled progestins and androgens as imaging agents for receptor-positive tumors of the breast and prostate.
Brandes
S J
SJ
Department of Chemistry, University of Illinois, Urbana 61801.
Katzenellenbogen
J A
JA
D000728:Androgens / Q000378:metabolism; D001943:Breast Neoplasms / Q000032:analysis / Q000000981:diagnostic imaging*; D005260:Female; D005462:Fluorine Radioisotopes / Q000378:metabolism; D006801:Humans; D008297:Male; D009277:Nandrolone / Q000031:analogs & derivatives; D009376:Neoplasms, Hormone-Dependent / Q000032:analysis / Q000000981:diagnostic imaging*; D011374:Progesterone / Q000031:analogs & derivatives; D045167:Progesterone Congeners / Q000378:metabolism; D011471:Prostatic Neoplasms / Q000032:analysis / Q000000981:diagnostic imaging*; D011485:Protein Binding; D011877:Radionuclide Imaging; D011944:Receptors, Androgen / Q000378:metabolism; D011960:Receptors, Estrogen / Q000378:metabolism; D012738:Sex Hormone-Binding Globulin / Q000378:metabolism; D013329:Structure-Activity Relationship; D013739:Testosterone / Q000031:analogs & derivatives; D014156:Transcortin / Q000378:metabolism
D000728:Androgens; D005462:Fluorine Radioisotopes; D045167:Progesterone Congeners; D011944:Receptors, Androgen; D011960:Receptors, Estrogen; D012738:Sex Hormone-Binding Globulin; D013739:Testosterone; D011374:Progesterone; D009277:Nandrolone; D014156:Transcortin